Post hoc analysis of a phase 3, cluster randomised clinical trial of peginterferon beta-1a to reduce transmission of SARS-CoV-2: effect of viral load on transmission and risk factors for hospitalisation - Milan 2023

COVID-19 treatments

Chair(s): Megan Crichton, Michal Shteinberg

Session type: Poster session

Post hoc analysis of a phase 3, cluster randomised clinical trial of peginterferon beta-1a to reduce transmission of SARS-CoV-2: effect of viral load on transmission and risk factors for hospitalisation

Samuel Montgomery

EVENTS HOME

Abstract

Previous presentation

Next presentation

Session content

Effects of prolonged corticosteroid therapy on lung abnormalities and symptoms after severe COVID-19 pneumonia with prolonged respiratory insufficiency

Nevenka Piskac Zivkovic

Poster

Abstract

Clinical trials of inhaled interferon beta-1a (SNG001) in COVID-19 patients in the home and hospital

Phillip D Monk

Poster

Abstract

Lactoferrin in Long COVID patients (LARGO): a randomized, double-blind, controlled trial

Anne-lotte Redel

Poster

Abstract

Lopinavir-ritonavir versus darunavir-norvir for hospitalized COVID-19 patients

Dora Paroczai

Poster

Abstract

Temporal development of non-pharmacological maximum therapies for COVID-19 inpatients

Sandhya Matthes

Poster

Abstract

Chronic COPD medications and CoViD-19 mortality- an observational study.

Anastasios Stringaris

Poster

Abstract

Tozorakimab in patients hospitalised with COVID-19: a phase 2, randomised adaptive platform study (ACCORD-2)

Hitesh Pandya

Poster

Abstract

The Effect of Inhaled Corticosteroid (ICS) Use in the Outcomes of COVID-19 Pneumonia among Patients 18 years old and Above Diagnosed with Asthma and COPD in a Tertiary Hospital: A Retrospective Cohort Study

Jay Andrew Ilagan

Poster

Abstract

Antiviral and anti-inflammatory effects of Erdosteine and MET-1 in SARS-CoV-2 in vitro infection

Sergio Strizzi

Poster

Abstract

Benefits of N-Acetylcysteine in the SARS-CoV-2 infection

Mª Angeles Galindo-andugar

Poster

Abstract

Is Anakinra effective and safe for severe COVID-19 disease? A Comprehensive Systematic Review of 44 studies including 3179 patients

Aliae Abd Rabou Mohamed-hussein

Abstract

Comparison of effectiveness between baricitinib and tocilizumab in severe COVID-19. A retrospective study.

Ioannis Tomos

Poster

Abstract

Remdesivir versus favipiravir in hospitalized patients with moderate COVID-19 pneumonia: A propensity score-matched retrospective cohort study.

Karuna Chavalertsakul

Poster

Abstract

A comparative study of the effectiveness between pulse regimen methylprednisolone versus high dose dexamethasone as the initial treatment of moderate covid-19 pneumonia: an open-label randomized controlled trial

Jakkrit Laikitmongkhon

Poster

Abstract

Virucidal efficacy of cetylpyridinium chloride lozenges against coronavirus and influenza virus

Graca Coutinho

Poster

Abstract

Bevacizumab in addition to standard of care did not shorten the time to improve hypoxemia in severe hypoxemic COVID-19 pneumonia in a prospective randomized controlled trial.

Jacques Cadranel

Poster

Abstract

Inhaled corticosteroids for post-hospital rehabilitation treatment of patients with COVID-19

Nataliia Chaplynska

Poster

Abstract

Samuel Montgomery

Abstract

Impact of low molecular weight heparin (LMWH) on SARS-CoV2 Infection: HEPARIN SARS-CoV2 clinical trial.

Remedios Otero Candelera

Poster

Abstract

CDN Connection Issue

The ERS International Congress 2023, Milan

#{title}